Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

This single-arm phase 1b/2 study (n=97) found a single cilta-cel infusion was associated with an overall response rate of 97% (67% complete response) in heavily pre-treated patients with multiple myeloma. The data from this study formed the basis of recent regulatory submissions.

Source:

The Lancet